2021 Fiscal Year Final Research Report

Changes in the immunological profile of gastric cancer stem cells due to irradiation

Research Project

PDF

Project/Area Number	19K09136
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 55020:Digestive surgery-related
Research Institution	Japanese Foundation for Cancer Research
Principal Investigator	KUMAGAI Koshi 公益財団法人がん研究会, 有明病院消化器外科, 医長 (40383848)
Co-Investigator(Kenkyū-buntansha)	若槻尊公益財団法人がん研究会, 有明病院消化器内科, 副医長 (60443876) 馬島哲夫公益財団法人がん研究会, がん化学療法センター分子生物治療研究部, 主任研究員 (30311228) 山口研成公益財団法人がん研究会, 有明病院消化器化学療法科, 部長 (10321845) 佐野武公益財団法人がん研究会, 有明病院, 病院長 (30215884)
Project Period (FY)	2019-04-01 – 2022-03-31
Keywords	胃癌 / 癌幹細胞 / 放射線
Outline of Final Research Achievements	To investigate the effects of radiation on cancer stem cells, we irradiated We cell lines derived from gastric cancer patients and compared changes in the expression of PD-L1 (Programmed cell Death 1-Ligand 1) and genes related to immune response. In cell lines derived from poorly differentiated adenocarcinoma, the proportion of PD-L1 expressing cells before irradiation was 4.8%, but it went up to 75% by irradiation of 8 Gy. On the other hand, the cell line established from the moderately differentiated adenocarcinoma had a PD-L1 expression rate of 17% before irradiation, and it was 28% even after irradiation of 8 Gy. We plan to further investigate the relationship between PD-L1 expression by irradiation and histological type, prognosis, etc. in the future.
Free Research Field	癌
Academic Significance and Societal Importance of the Research Achievements	本研究では、放射線照射によってがん免疫にかかわる細胞表面マーカーの代表であるPD-L1(Programmed cell Death 1- Ligand 1）の発現がどのように変化するかを検討した。その結果、放射線照射によって胃がん細胞のPD-L1発現は増強するが、その程度は組織型によって異なる可能性が示唆された。免疫チェックポイント阻害薬と放射線療法の併用によって腫瘍縮小効果が増強する機序の解明につながる、興味深い知見が得られた。